ArticleBJC reports2025
IL-6R expression is an independent prognostic factor in high-grade serous ovarian cancer.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HPV-driven inflammatory pathways in ovarian carcinogenesis: molecular mechanisms and emerging therapeutic interventions.Journal of ovarian research · 2025Review
- Role of depression-mediated alterations in pro-inflammatory cytokines in carcinogenesis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHGSOC is the leading cause of death among all gynaecological malignancies. We recently identified that genomically unstable cancers that display high levels of chromosomal instability, including HGSOC, rely on a cGAS/STING/IL-6R autocrine loop for survival. Here, we determined the prevalence of IL-6R expression in HGSOC samples to identify patients that could potentially benefit from treatment inhibiting IL-6R.
methodsImmunohistochemical staining of IL-6R and STING in a well-characterized cohort of advanced-stage HGSOC patients (N = 268) was digitally quantified. After excluding patients with less than two cores or an "unknown" alive status, the resulting data of 230 patients was correlated with overall survival, and relevant histopathological, clinical, genetic, and therapeutic variables were assessed.
resultsThe majority of patient cores were positive for IL-6R and STING, where the staining intensity for IL-6R was more varied, while STING had a more consistent expression. We found that IL-6R expression is associated with improved survival. Multivariate analyses also identified that IL-6R, BRCA1/BRCA2 mutation, primary treatment, and surgical outcome are strong independent prognostic factors of overall survival.
conclusionsOur findings suggest that ~37% of HGSOC patients might benefit from treatment targeting IL-6R. The high prevalence and underlying molecular data warrant further investigation in a clinical trial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.